Background. In view of the alarming increase in the number of people with diabetes mellitus (DM), a rising number of patients with diabetic kidney disease (DKD), end-stage renal disease (ESRD) and cardiovascular disease (CVD) is forecasted. It is therefore imperative to re-visit the natural history of DKD and to identify potential risk factors, which may enhance the progression of the disease and its complications. Methods. The medical records of 270 Type 2 diabetic chronic kidney disease patients followed up at the Sheffield Kidney Institute between 2000 and 2008 were reviewed. Various socio-demographic, clinical and biochemical parameters (baseline and follow-up parameters) were retrospectively collected from the patients' database. Progression of DKD was evaluated by evaluation of the rate of decline of estimated glomerular filtration rate (eGFR) as calculated from the simplified Modification of Diet in Renal Disease formula [progressors: loss of glomerular filtration rate (GFR) >2 mL/min/1.73m 2 /year] as well as by the progression pattern based on the slope of GFR changes. Variables associated with progression in univariate analysis were examined by multivariate analysis to determine the factors independently associated with DKD progression. Results. The majority of the study populations were males (66.7%) and Caucasians (88%). Ninety-four patients (34.8%) had progressive, whereas 176 (65.2%) had nonprogressive DKD. The rate of eGFR decline in progressors was À3.57 6 1.45 mL/min/1.73m 2 /year compared to À1.31 6 0.23 mL/min/1.73m 2 /year in non-progressors. The following parameters discriminated progressors from non-progressors by univariate analysis: baseline-blood pressure (BP) parameters, eGFR and proteinuria as well as serum uric acid. We also observed that area under the curve for follow-up systolic blood pressure (SBP), glycosylated haemoglobin (HbA1c) and proteinuria were significantly higher among the progressors (P ¼ 0.043, P ¼ 0.02 and P ¼ 0.001, respectively). Independent determinants of DKD progression in this study in an adjusted logistic regression model were baseline HbA1c [odds ratio (OR), 2.27; 95% confidence interval (CI), 1.14-4.54], baseline SBP (OR, 1.23; 95% CI, 1.06-1.41), baseline proteinuria (OR, 3.24; 95% CI, 2.1-5.38), baseline serum uric acid (OR, 1.16; 95% CI, 1.09-1.39) and vascular co-morbidities (OR, 1.61; 95% CI, 1.02-2.54). Percentage changes in the key parameters (BP, HbA1c and proteinuria) during the first year of the study did not affect the rate of eGFR decline. Conclusions. Baseline HbA1c, SBP, proteinuria and serum uric acid together with the presence of vascular comorbidities are strongly and independently associated with faster DKD progression. A further prospective observational study is currently undertaken to evaluate these findings and to determine the predictive value of other biochemical peptides and cellular markers on DKD outcome.
Introduction
The perceived global rise of chronic kidney disease (CKD) is a significant public health issue that may affect up to 10% of the adult population worldwide [1, 2] . Diabetes mellitus (DM) remains the most common cause of end-stage renal disease (ESRD) in the developed world, and diabetic kidney disease (DKD) is the leading specific primary renal diagnosis for patients commencing renal replacement therapy (RRT) [3] . According to the World Health Organization (WHO) data, the number of people with DM worldwide, currently~171 million, is set to double within the next 20 years, and the increase will be most notable in the developing world, where the number of patients with DM is due to reach 366 million by 2030 with Type 2 diabetes mellitus (T2DM) accounting for 90% of cases worldwide [4, 5] . Approximately 25-40% of patients with T2DM develop kidney damage and CKD [6] . Moreover, these patients are at the greatest risk for cardiovascular disease (CVD), morbidity and premature mortality engendered by the combination of DM and CKD, thus imposing a significant burden on both patients and health care costs and resources [7, 8] . Microalbuminuria has been recognized as a marker of early glomerular and vascular damage [6] . The United Kingdom Prospective Diabetes Study (UKPDS) showed that once patients with DM develop microalbuminuria, death rates outpace CKD progression by close to 2:1 and approach 20% per year [9] . Furthermore, recent reports from United States Renal Data System (USRDS) revealed that elderly patients who have the common triad of DM, CKD and heart failure are five times more likely to die than to progress to ESRD. The death rate was 38.6%, while only 6.8% of patients reached ESRD, at the end of 2 years of follow-up [10] . However, the natural history of CKD in T2DM is heterogeneous and is predominantly associated with atherosclerosis [11] . The progression of CKD in T2DM varies considerably between individuals and the risk factors that determine disease outcome have not been fully understood. With this in mind, we sought to study retrospectively the natural history of DKD progression and to identify the potential possible risk factors, which may hasten the disease progression.
Materials and methods

Study design and population
The study was a single-centre retrospective cohort study based on a review of the electronic database of patients with T2DM and CKD. We performed a comprehensive search of the computerized patient record system (PRO-TON) at the Sheffield Kidney Institute (SKI) Northern General Hospital NHS Trust, Sheffield, UK, to find T2DM patients with evidence of kidney damage/or CKD. The medical records of~1000 patients who attended the SKI outpatient clinic from 1 January 2000 through 31 December 2008 were reviewed. The inclusion criteria of the study were: T2DM patients with estimated glomerular filtration rate (eGFR) <60 mL/min to 15 mL/ min/1.73m 2 (CKD Stages 3-4) at the time of referral/baseline, adult patients aged !18 years with at least 3 years follow-up since referral to SKI and who are not on any form of RRT at baseline (either dialysis or transplantation). Whereas, diabetic patients with eGFR >60 mL/min/1.73m 2 (i.e. CKD Stages 1 and 2), patients who presented with acute kidney injury (AKI) and CKD due to other causes than T2DM were excluded. The patients who started dialysis before commencing our study observational period were also excluded. We also excluded those patients who started RRT within a short observation period (<3 years) as our pre-specified observation time was a minimum of 5 years. Therefore, all 24% of the cohort who progressed to ESRD were included in our analysis as they fulfilled our inclusion criteria. Clearly, we did not include their parameter changes (biochemical and clinical) once they started dialysis. Of these, only 270 patients were ultimately found to be suitable for the study.
Parameters
Demographic parameters. The following socio-demographic parameters were collected and retrospectively analysed for each patient: age at presentation, gender and race (patients were broadly categorized as Caucasians and non-Caucasians). All those categorized as White British were grouped as Caucasians and all those defined otherwise (including all ethnic minorities and Indo-Asians) were termed non-Caucasians. History of smoking was assessed from the patients' medical records; patients were classified into smokers, non-smokers and not known. Ex-smokers were considered as smokers.
Clinical and biochemical parameters. Various biochemical and clinical parameters were retrospectively collected from the patients' database at baseline and over the entire period of follow-up for each patient. Comorbidities including ischaemic heart disease (IHD), stroke, peripheral vascular disease (PVD) and malignancy were also recorded. Clinical variables: baseline body mass index (BMI) was calculated as weight in kilograms per square metre (kg/m 2 ) and divided into three categories on the basis of defined criteria [12] : normal weight (BMI ¼ 18.5-24.9 kg/m 2 ), over weight (BMI ¼ 25-29.9 kg/m 2 ) and obese (BMI ! 30 kg/m 2 ), respectively. Blood pressure (BP) was recorded for all participants at baseline and every 3-6 months over the whole period of follow-up. The mean arterial blood pressure (MAP) was calculated from the following equation:
. Biochemical variables such as serum creatinine, lipids (cholesterol and triglyceride levels), albumin, uric acid, haemoglobin, calcium, phosphorus, glycosylated haemoglobin (HbA1c)% and parathyroid hormone (PTH) levels were all recorded. Urinary proteinuria was subdivided according to the daily protein excretion into two categories: either proteinuria <1 g/day or !1 g/day. These cut-offs were chosen as it is generally thought that prognosis of CKD patients is much better in individuals with proteinuria <1 g/24 h [13] . Treatment: reninangiotensin system (RAS) blockade was defined as treatment with angiotensin-converting enzyme inhibitors (ACEI) and/or angiotensin receptor blockers (ARBs). We also recorded treatment with statins.
DKD progression
The progression of DKD was evaluated by rate of decline of eGFR as calculated by using the Modification of Diet in Renal Disease (MDRD) study equation [14] 30:742ðfor womenÞ31:212ðif the subject is blackÞ
The rate of eGFR fall per year was used to assess the progression of DKD and calculated by the difference in eGFR (mL/min/1.73m
2 ) at presentation and the last available reading:
ðLast eGFR À Baseline eGFRÞ=Followup period in year:
The eGFR fall per year for all patients was used to identify their DKD progression status. Patients with !2 mL/min/1.73m 2 /year eGFR reduction were classified as progressors, whereas those with <2 mL/min/1.73m 2 / year were classified as a non-progressors and those with eGFR improvement !2 mL/min/year were classified as regressors.
Consequently, the non-progressors group included patients with a rate of eGFR decline between À1 and À2 mL/min/year; this was intentional as we considered average age-related decline to be around À1 mL/min/year [15] and considering variation in serum creatinine measurement, we did not want to contaminate our progressors group with some age-related borderline progressors.
We also evaluated the disease progression based on the slope pattern of eGFR change (mL/min/1.73m 2 /year) for each patient throughout the entire follow-up period (at least three measurements) by regression coefficient analysis using all calculated eGFR values [16] . Accordingly, patients were considered either to be progressors (slope significantly negative and < À2 mL/min/year), regressors or improved (slope significantly positive, > 12 mL/min/year) or stable or non-progressors, when the slope is neutral (i.e. with a decline rate between 12 and À2). We choose to use the annualized rate of eGFR loss as it is easier for practicing nephrologists to use. The concordance between the two methods also gave credence and validity to our cut-off choice of À2 mL/min/year as a definition for progressors.
Percentage changes of key variables
The impact of changes in the potential variables such as HbA1c, proteinuria and hypertension during the first year of observation on the progression of DKD outcome was evaluated as percentage changes from baseline as follows:
We also calculated the area under the curve (AUC) for these potential confounding variables to evaluate their impact on the disease progression.
Statistical analysis
All analyses and calculations were performed using the Statistical Package for Social Sciences (SPSS, Inc., Chicago, IL; version 15.0.1). Continuous data are described as mean and SD or median and interquartile range (25-75th percentiles) in case of skewed distribution. Categorical data are reported as proportions (percentages). Data were analysed using the parametric-independent samples t-test for comparing means of subgroups or by Mann-Whitney U-test in case of the data was not normally distributed. Chi-square test was used to compare the frequency distribution of categorical variables. Pearson's correlation coefficient (r) was used to examine the associations between different variables of the study. Univariate regression analysis was used for modelling with annual reduction in eGFR as the dependent variable. All variables that attained a P-value <0.01 on univariate analysis were included in subsequent multivariate multiple logistic regression analysis to produce the predictive models based on DKD progression status. All analyses were done with 95% confidence intervals (CI) and all P-values were two tailed and the level of significance was determined at P <0.05.
Results
Demographic and clinical characteristics of all patients who met the study inclusion criteria are shown in Table 1 . The mean age of patients was 69.6 AE 11 years with 64% aged !65 years. The mean observation/follow-up time was 5.2 AE 1.8 years. The participants were predominantly Caucasian (88%), male (66.7%) and 41.2% (n ¼ 110) where found to be smokers. The mean baseline eGFR was 33.6 AE 11.3 mL/min/1.73m 2 and 62.6% had CKD Stage 3. Patients' BMI was 31 AE 6.6 kg/m 2 . Of the participants, 13.4% had normal weight, 39.2% were overweight and the majority (47.5%) was obese, BMI !30 kg/ m 2 . The known duration of the T2DM was 15.4 years (2-40 years). Vascular co-morbidities were recorded among 140 (51.9%) of the study population. A history of IHD (angina/or myocardial infarction) was the most common co-morbidities affecting about 31.5%, whereas 12% had cerebrovascular disease (CVD), 13.5% had PVD (history of intermittent claudication/or amputation) and 9.9% had malignancy. There was a significant difference in comorbidities among the progressors compared to nonprogressors group (P ¼ 0.004). At the time of this analysis, the majority of the patients (62.6%) were still being followed up at the outpatient renal clinic, whereas 6% (n ¼ 16) had been discharged. Twenty-four per cent (n ¼ 65) of the study patients had reached ESRD and were on dialysis, while 7.4% (n ¼ 20) had died. However, the death rate had reached 12% when data of patients on dialysis were included. The majority of the patients (82%) were treated with statins and ACEI/or ARBs were used by 61.5% of the study population. The baseline and follow-up biochemical parameters of all patients are given in Table 2 . Table 3 summarizes the main differences between progressor and non-progressor DKD patients. The mean rate of eGFR decline during the study period was À1.46 mL/ min/1.73m 2 /year (range À9 to 15) as assessed by the annual reduction of eGFR. Ninety-four patients (34.8%) had progressive disease with annual eGFR decline À3.57 AE 1.45 mL/min/1.73m 2 /year, whereas 176 patients (65.2%) had non-progressive DKD (D À1.31 AE 0.23 mL/min/ 1.73m 2 /year). On the other hand, 147 (38.2%) were progressors and 61.8% were stable when evaluated by the progression pattern based on the slope. As mentioned above, the progression pattern based on slope validates our eGFR cut-off point for progressors. We have decided arbitrary to choose the annual rate of decline rather than slope for subsequent analyses as it is easier to calculate in daily practice compared to the more elaborate regression analysis to estimate the eGFR slope change against time. Males and females were almost equally distributed among both groups. The mean age for progressor group was slightly lower than non-progressors. The main discriminate parameters which showed a significant association with progression were vascular co-morbidities, diabetic retinopathy and race. All BP parameters were higher in the progressors group (Table 3) . Similarly, the levels of proteinuria, baseline serum uric acid and creatinine were higher in the progressors. Furthermore, diabetes control as reflected by HbA1c was better controlled in the non-progressors group. On the other hand, no significant differences were observed in percentage of changes/control during the first year of follow-up in HbA1c, proteinuria and BP parameters between two groups. The impact of exposure to hypertension, HbA1c and proteinuria was highly significant on the disease progression as judged by differences in the AUC during the observation time (Table 3) .
Progression of DKD
Correlation between DKD progression and other study variables Table 4 shows the correlation between different study variables and disease progression. This was achieved by using Pearson's correlation coefficient (r). Baseline systolic blood pressure (SBP), MAP, higher HbA1c, greater proteinuria and elevated serum uric acid were found to be directly correlated to DKD progression. Whereas inverse significant correlations were evident with serum albumin at presentation as well as at follow-up. Conversely, there were no significant associations between BMI, follow-up serum uric acid and follow-up HbA1c and rate of eGFR decline. Noticeably, young age and smoking were significantly correlated with rapid decline of kidney function (Table 4) .
Univariate regression analysis
The results of unadjusted simple linear regression analysis of baseline variables related to the annual decline of eGFR are illustrated in Table 5 . Percentage changes of HbA1c, BP and proteinuria did not affect the rate of decline of DKD. Also, the calculated AUC for potential risk factors did not predict the faster progression of DKD.
Prediction of DKD progression
A multivariate logistic regression analysis was used to predict DKD progression with adjustment for variables that attained P < 0.05 in univariate analysis. The overall R 2 of the model was 29.4%, r ¼ 0.46 and P-value < 0.0001. Independent determinants of DKD progression in this study in an adjusted logistic regression model for age, race and gender (Table 6) were baseline HbA1c, SBP, proteinuria, serum uric acid and presence of vascular co-morbidities. All P-values for associations of disease progression with the other baseline variables were >0.05.
Discussion
The majority of the elderly population in this retrospective cohort observation study had minimal progression of CKD over a median follow-up period of 6 years and low level proteinuria. The latter is inconsistent with the conventional model of progressive DKD as one would expect much heavier proteinuria with advanced renal insufficiency and progressive CKD. In fact, the rate of progression of CKD in the majority of those studied could be considered consistent with age-related decline in kidney function. This is at variance with the older prevailing assumptions that the majority of those with CKD Stages 3-4 diabetic nephropathy progress relentlessly to ESRD [17] . It is consistent with our impression that the majority of patients followed up at the outpatient clinic of the SKI are elderly patients with T2DM and severe vascular atherosclerotic disease whose renal function does not seem to progress and are not proteinuric and whose natural history is more akin to that of patients with hypertensive and ischaemic vascular nephropathy. This is consistent with a number of recently published observations [18, 19] .
In this study, we took extra care to ascertain the nature of progressive CKD. We were concerned that reliance on two serum creatinine values (baseline and end of study) could be misleading. So, we evaluated DKD progression by calculating the rate of decline of eGFR by the simplified MDRD formula [progressors: loss of glomerular filtration rate (GFR) >2 mL/min/1.73m 2 /year] as well as by progression based on the slope pattern of eGFR change throughout the whole follow-up period by regression coefficient analysis using all calculated eGFR values. Interestingly, the percentage of progressor and non-progressor DKD patients was almost identical by using the two methods. This has been achieved by including patients with a minimum 3 years of follow-up and at least six eGFR measurements; the requirements to establish a valid rate of decline in renal function. As it has previously been suggested that the applied eGFR method should be more accurate and precise, when serum creatinine measurements were repeated every 6-12 months, and the observation period should extend to at least 2 years [20] . Moreover, the National Kidney Foundation (NKF) currently recommends using this prediction equation's slope regression analysis to calculate eGFR and monitor progression of CKD [21] .
In our study, we have observed that a faster DKD progression was strongly predicted by baseline proteinuria on multivariate analysis. Of interest, the level of proteinuria was modest in the majority of the patients in this study. This may be due to the above assumption that many suffer predominantly a hypertensive, atherosclerotic and ischaemic nephropathy rather than a typical heavily proteinuric diabetic nephropathy. On the other hand, it may be due to the use of inhibitors of the renin-angiotensin aldestrone system (RAAS) and their known impact on reducing proteinuria. Proteinuria has been considered to play a central role in the pathogenesis of progressive renal dysfunction [22] and is now considered a well established and independent risk factor for CVD [23] . When the risk factors for progression in renal disease were evaluated in a post hoc analysis of 1513 patients with T2DM with renal impairment enrolled in Reduction of End points in NIDDM with Angiotensin II Antagonist Losartan (RENAAL) study, baseline albuminuria was the strongest and most consistent independent risk factor for time to reach the composite end point of doubling serum creatinine or developing ESRD [24] . Furthermore, several lines of evidence have shown that reduction of proteinuria in diabetic patients by alteration of the RAAS provides a wide range of therapeutic benefits in the prevention of disease progression [25] . However, progressive glomerulosclerosis and tubulointerstitial fibrosis in DKD have been described even in the absence of proteinuria [26] . Also, in the ONTARGET study, a reduction in proteinuria by a combination of an ACEI and ARBs decreased proteinuria while worsening the rate of decline in GFR [27] . This may be due to the fact that many of the patients included in this study were older with atherosclerotic vascular disease, thus more prone to ischaemic nephropathy than typical diabetic, proteinuric, nephropathy. Also, the absence of a predictive value for being on an inhibitor of the RAAS in relation to DKD progression in our study somewhat argues against an impact of such a therapy in our older diabetic group of patients with moderate baseline proteinuria. The current study suggests an association between hyperglycaemia and progression in DKD. There is an increasing body of evidence as well as controversy relating to the benefits of intensive control of hyperglycaemia and prevention of diabetic microvascular complications [28, 29] . Although, recent observations of intensive glycaemia control have raised concerns about increased mortality [30] . Baseline HbA1c was among the strongest determinants of disease progression in this study. This is in agreement with Bash et al. [31] who found a strong positive association between HbA1c concentration and CKD progression in 1871 adult patients after 11 years of follow-up even in the absence of albuminuria and retinopathy. However, the effects of intensive glycaemic control on prevention of macrovascular complications such as coronary artery disease, CVD and PVD are less certain, particularly in T2DM. This has been showed in 10 years follow-up UKPDS study in patients with T2DM as it did not demonstrate any risk reduction for myocardial infarction and death from any cause [32] . Yet, more recent studies, including ACCORD, ADVANCE and the VADT that targeted even lower HbA1C goals (<6 to 6.5%), failed to show CVD risk reduction with more intensive glycaemic control regimens and raised concerns about increased risk [33] [34] [35] . In fact, the ACCORD study failed to show an impact of tight glycaemic control on the progression rate of DKD [33] . Of interest in that respect, as in our study, it was the baseline quality of diabetes control that seemed to predict subsequent progression in spite of the fact that subsequent improved glycaemic control during follow-up seemed to have little impact on the predetermined rate of progression.
With regard to hypertension, our study indicated that hypertension is a strong predictor for the progression of DKD. All BP parameters were found to be correlated positively with the annual reduction of eGFR. There were significant differences in baseline and follow-up BP indices between progressors and non-progressors. In multivariate logistic regression analysis, baseline SBP was independently associated with that of eGFR decline. This could be explained by the fact that older T2DM patients suffer from isolated systolic hypertension. This is consistent with previously published studies linking the association of BP and DKD progression [36, 37] . Rossing et al. [18] reported that baseline SBP was one of the main predictors of GFR decline in the analysis of 227 Caucasian patients with DKD from the Steno Diabetes Centre in Denmark, in whom the mean follow-up time was 6.5 years. The increased BP was also one of main predictors in Irbesartan Diabetic Nephropathy Trial (IDNT) [36] , another large clinical trial in T2DM patients. In contrast, in the RENAAL trial [24] , baseline BP was not a predictor of progression. However, in a recent post hoc analysis of RENAAL, follow-up SBP, but not DBP, BP was a risk for progressive nephropathy; however, this effect was only seen when SBP was >140 mmHg. Thus, taken together, the findings of interventional and observational studies suggest that early improvement in BP control in patients with both T2DM and hypertension is known to be important in preventing adverse cardiovascular and renal outcomes in diabetic patients, but it appears that good BP control must be continued if the benefits are to be maintained [37] . Of interest, we noted a significant improvement in SBP and DBP during the first year of followup at the SKI. However, such improvement did not impact on subsequent eGFR rate of decline. This may be due in this older group of atherosclerotic diabetic patients to the predetermined ischaemic damage. Also, we could not demonstrate any beneficial effects of using ACEI/or ARBs. But this may be explained by the nature of the patients studied as it has been previously reported by Suissa et al. [38] in a similar group of older T2DM with CKD that ACEI usage may have accelerated the decline of kidney function rather than improved it. Furthermore, the recent observations from the Joslin clinics [39] showing no reduction in the incidence of ESRD in older diabetic patients over the last three decades (before and after introduction of RAS blockade) argues against a protective effect of these agents on the natural history of DKD in this age group. This may also be due to our assumption that the majority of these patients suffer from ischaemic nephropathy rather than hyperperfusion and hyperfiltration-diabetic nephropathy as in younger Type 1 diabetic (T1DM) patients upon which the concept of angiotensin nephrotoxicity has been assumed [40] . However, we recognize that our study was not designed to evaluate treatment effects due to the risk of confounding by indication in observation study.
We have observed, during the first year of study, some remarkable reduction in the potential variables implicated in DKD progression, namely, a 5.2% reduction in HbA1c, 6.3 and 5.9% reduction in SBP and DBP, respectively, as well as 15.8% reduction in proteinuria. However, surprisingly, the noted improvement in these parameters upon closer follow-up at the SKI did not impact on the rate of progression of DKD.
It has been established that coronary heart disease (CHD) is the leading cause of death in patients with DM and CKD. In the current study, more than half of the study population had vascular co-morbidities and CHD (angina, myocardial infarction) was the most common co-morbidities affecting nearly 32% of the study population. The WHO Multinational Study of Vascular Disease in Diabetes [41] involved 1188 patients with T1DM and 3234 patients with T2DM compared with patients with no proteinuria. It showed that proteinuria was associated with significantly increased mortality from CVD and all other causes of death. The risk factors for CHD were evaluated in 2329 T1DM patients in the EURDIAB Prospective Complication Study and found a strong predictive value of baseline albuminuria [42] . Whether this is a causal relationship or merely the reflection that those diabetic individuals who have albuminuria, a marker of CVD, have more severe underlying CVD therefore are more likely to die from CVD, remains to be determined [43] . In our population, the presence of underlying CVD was independently associated with the progression of DKD. Similar observations have been reported in a range of older patients with CKD suggesting that in this age group, progressive atherosclerosis impacts on the progression of the underlying ischaemic and atherosclerotic nephropathy [44, 45] .
In the current study, the majority of the populations were obese with a BMI of !30 kg/m 2 . It is known that the increase in the prevalence of T2DM is strongly linked to the upsurge in obesity and~197 million people worldwide have impaired glucose tolerance, mainly because of obesity and the associated metabolic syndrome [46] . This number is expected to rise up to 420 million by 2025. In this study, baseline BMI was not an independent factor affecting DKD progression. In fact, obesity is known to lead to ESRD and death from CKD through DM and hypertension; however, additional haemodynamic, metabolic and inflammatory mechanisms may also be contributing factors [47] . Moreover, recent studies have found waist circumference to be a better marker of central obesity than BMI for risk of cardiovascular events, CKD and all-cause mortality [48, 49] .
Baseline serum uric acid correlated directly with the annual eGFR decline and predicts the DKD progression. Hyperuricaemia has been reported to be associated with increased risk of renal insufficiency as well as cardiovascular events. A recent study carried out by Fukui et al. [50] shows that serum uric acid concentration is associated with microalbuminuria and atherosclerosis in patients with T2DM. As with albuminuria, it may be that hyperuricaemia reflects the severity of systemic vascular disease and more specifically renal ischaemia, thus not surprisingly predicts the rate of progression of ischaemic diabetic nephropathy.
Diabetic retinopathy was diagnosed in 43% of the study population. This is in tandem with the results from Nation Diabetes Data Group where proliferative diabetic retinopathy found to affect up to 35-45% of diabetic patients > 15-25 years of disease duration and is considered as a major cause of blindness [51] . The current study revealed a higher rate of diabetic retinopathy in the progressors group but it did not influence the disease outcome. The association of retinopathy with nephropathy is particularly strong in T1DM, while is less well documented in T2DM. However, we are aware that data were not available for all patients and this consequently may affect the results.
In agreement with our findings, previous studies in T2DM patients have failed to demonstrate a significant correlation between hyperlipidaemia and rate of decline in GFR. This could be explained by the confounding influence of other risk factors and the impact of interventions [36, 52] . Smoking was not demonstrating any significant impact on the rate of eGFR decline. This may be attributable to lack of sufficient information in the medical records of patients. In the RENAAL study, smoking at baseline also did not affect the renal outcome [24] . However, it is possible that smokers may have been more likely to die of cardiovascular complications before reaching the renal end points. In fact, much of the literature documenting an association between smoking and kidney disease is limited by relatively short-term follow-up periods. In contrast, smoking was a significant predictor of progression of kidney disease in diabetic patients in a recent study carried out by Cignarelli et al. [53] .
Our study does have some limitations. Firstly, the data for this study were collected retrospectively. Also, some patients had an acceptable number of readings for the different study variables, while others had some missing readings for clinical and biochemical data. Most patients were already on anti-hypertensive medications at the time of study enrolment that could have affected the results for the baseline analysis of hypertension. Furthermore, the nature of CKD in our population study was mainly elderly patients making it more likely to include a significant percentage of patients suffering from ischaemic nephropathy and hypertensive nephrosclerosis on a background of DM. Finally, because patients in this study were predominantly elderly Caucasian males therefore these results may not necessary be extrapolated to other populations. Despite these limitations, we believe that our findings are relevant to usual clinical practice.
